Endo International PLC (NASDAQ:ENDP) shares dropped 3.2% during mid-day trading on Friday . The company traded as low as $17.30 and last traded at $17.43, with a volume of 1,866,191 shares trading hands. The stock had previously closed at $18.00.

ENDP has been the subject of a number of recent research reports. Deutsche Bank AG reissued a “buy” rating and set a $61.00 price target (down from $65.00) on shares of Endo International PLC in a research report on Monday, April 18th. Citigroup Inc. decreased their target price on shares of Endo International PLC from $72.00 to $40.00 and set a “buy” rating for the company in a report on Friday, April 29th. Nomura Holdings Inc. reaffirmed a “buy” rating on shares of Endo International PLC in a report on Saturday, April 2nd. Stifel Nicolaus decreased their target price on shares of Endo International PLC from $90.00 to $75.00 and set a “buy” rating for the company in a report on Friday, May 6th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $35.00 target price (down from $65.00) on shares of Endo International PLC in a report on Saturday, May 7th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $40.32.

The stock’s market cap is $3.90 billion. The firm’s 50-day moving average is $16.85 and its 200 day moving average is $32.02.

Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings results on Thursday, May 5th. The company reported $1.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.04 by $0.04. During the same period in the previous year, the company posted $1.17 earnings per share. The firm had revenue of $963.54 million for the quarter, compared to analysts’ expectations of $960.96 million. The business’s quarterly revenue was up 34.9% compared to the same quarter last year. On average, analysts forecast that Endo International PLC will post $4.56 EPS for the current fiscal year.

In other news, Director Arthur J. Higgins purchased 11,000 shares of the firm’s stock in a transaction on Tuesday, May 10th. The stock was acquired at an average cost of $15.42 per share, with a total value of $169,620.00. Following the completion of the transaction, the director now owns 45,623 shares in the company, valued at approximately $703,506.66. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Paul Campanelli purchased 13,000 shares of the firm’s stock in a transaction on Tuesday, May 10th. The shares were purchased at an average cost of $15.53 per share, with a total value of $201,890.00. Following the completion of the transaction, the insider now owns 201,069 shares of the company’s stock, valued at approximately $3,122,601.57. The disclosure for this purchase can be found here.

Several hedge funds have recently added to or reduced their stakes in the stock. Advantus Capital Management Inc raised its stake in Endo International PLC by 2.4% in the fourth quarter. Advantus Capital Management Inc now owns 19,971 shares of the company’s stock valued at $1,223,000 after buying an additional 476 shares during the last quarter. Quantitative Investment Management LLC bought a new position in shares of Endo International PLC during the fourth quarter valued at approximately $2,650,000. BNP Paribas Arbitrage SA raised its position in shares of Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock valued at $16,737,000 after buying an additional 12,234 shares during the last quarter. Mcclain Value Management LLC raised its position in shares of Endo International PLC by 45.6% in the fourth quarter. Mcclain Value Management LLC now owns 334,302 shares of the company’s stock valued at $20,466,000 after buying an additional 104,705 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Endo International PLC by 7.8% in the fourth quarter. New York State Common Retirement Fund now owns 517,200 shares of the company’s stock valued at $31,663,000 after buying an additional 37,500 shares during the last quarter.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.